Media Contact

Larissa Doucette

Inspections of 30 entities engaged in compounding are underway by Food and Drug Administration (FDA) inspectors as part of the agency’s response to the 2012 meningitis outbreak linked to contaminated compounded injectable drugs. Facilities in 11 states have been inspected to date, and the agency plans to continue inspections over the next couple of months. Inspections are focused on facilities compounding sterile injectable drugs and those with a history of problems linked to patient illness, reports The Washington Post.